Voxelotor (hemolytic anemia due to sickle cell disease, patients aged ≥ 12 years, monotherapy or combined with hydroxycarbamide)


  • Active Substance: Voxelotor
  • Name: Oxbryta®
  • Therapeutic area: Sickle cell disease
  • Pharmaceutical company: Global Blood Therapeutics Germany GmbH

Time table:

  • Start: 15.05.2022
  • Final decision by G-BA: 03.11.2022

Final decision:

  • Hint for a non-quantifiable additional benefit